Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Pancreatic Neoplasms 18Carcinoma, Non-Small-Cell Lung 17Urinary Bladder Neoplasms 14Lung Neoplasms 11Ovarian Neoplasms 10Nasopharyngeal Carcinoma 9Neoplasm Metastasis 8Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Biliary Tract Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Lymphoma, Non-Hodgkin 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Sarcoma 2Rectal Neoplasms 2Osteosarcoma 2Melanoma 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leiomyosarcoma 2

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Gemcitabine × 30 days × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT04807816 2026-05-05

TARSARC

Institut Bergonié

Phase 2 Completed
58 enrolled
Sarcoma

Leiomyosarcoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡